Understanding QT Prolongation
QT prolongation is a potentially life-threatening cardiac side effect caused by dozens of commonly prescribed medications. This guide explains what QT prolongation is, which drugs carry this risk, and how patients and providers can minimize it.
What Is the QT Interval?
To understand QT prolongationQT Prolongation A delay in the electrical repolarization of the heart's ventricles, visible on an ECG as a lengthened QT interval. Drug-induced QT prolongation increases the risk of a dangerous heart rhythm called to
The QT interval is the time from the beginning of the Q wave to the end of the T wave — measured in milliseconds on the ECG. This interval represents the total time it takes for the ventricles (the heart's lower chambers) to electrically activate (depolarize) and then reset (repolarize) in preparation for the next heartbeat.
The QT interval is not fixed — it shortens at faster heart rates and lengthens at slower rates. Clinicians use the corrected QT interval (QTc) to account for heart rate, with QTc values above approximately 440–450 ms in men and 460–470 ms in women generally considered prolonged.
What Is QT Prolongation?
QT prolongation means that ventricular repolarization is taking abnormally long. At the cellular level, this occurs when drug molecules block specific cardiac ion channels — particularly the hERG (human Ether-à-go-go-Related Gene) potassium channel that carries the rapid delayed rectifier potassium current (IKr). This channel is critical for repolarization; blocking it slows the process and lengthens the QT interval.
QT prolongation itself is not a symptom — it is an electrical measurement. Most people with drug-induced QT prolongation experience no immediate symptoms. The danger lies in the risk of a life-threatening arrhythmia called torsades de pointes that can emerge on the background of a prolonged QT interval.
Torsades de Pointes: The Dangerous Arrhythmia
Torsades de pointes (TdP) — French for "twisting of the points" — is a form of polymorphic ventricular tachycardia (rapid, disorganized beating of the ventricles) that is distinctive on ECG: the amplitude of the QRS complexes appears to rotate around the isoelectric baseline, giving the arrhythmia its descriptive name.
TdP is dangerous because: 1. It dramatically reduces cardiac output, causing sudden lightheadedness, syncope (fainting), or cardiac arrest. 2. It can degenerate into ventricular fibrillation — a completely disorganized cardiac rhythm incompatible with life — within seconds.
Fortunately, drug-induced TdP is a rare event even among patients with QT prolongation. The absolute risk for most patients on QT-prolonging drugs is low — but not negligible, particularly in those with multiple risk factors.
Drug Classes That Prolong QT
The list of drugs associated with QT prolongation is long and crosses many therapeutic categories. The following are among the most clinically significant:
Antiarrhythmics (Highest Risk)
Paradoxically, several drugs used to treat abnormal heart rhythms can themselves cause QT prolongation and TdP: - Class IA: Quinidine, procainamide, disopyramide - Class IC: Flecainide (primarily at high doses) - Class III: Sotalol, dofetilide, ibutilide, amiodarone (amiodarone prolongs QT but rarely causes TdP — an unexplained paradox)
Antibiotics and Antifungals
- Fluoroquinolones: Moxifloxacin > ciprofloxacin > levofloxacin (varies by drug)
- Macrolides: Azithromycin, clarithromycin, erythromycin. Azithromycin received heightened attention after a 2012 study suggested increased cardiovascular mortality; risk is modest in healthy individuals.
- Chloroquine and hydroxychloroquine: Particularly with the high doses used off-label for COVID-19 in 2020, which prompted FDA safety warnings.
- Antifungals: Fluconazole, voriconazole, ketoconazole.
Antipsychotics
Many antipsychotics block the hERG channel and prolong QT: - Haloperidol (especially IV formulation at high doses): Well-documented QT prolongation. - Thioridazine: Withdrawn from some markets due to QT risk. - Ziprasidone: One of the highest QTc-prolonging atypical antipsychotics. - Quetiapine, risperidone, olanzapine: Moderate QT effects. - Clozapine: Variable risk.
Antidepressants
- Tricyclic antidepressants (TCAs): Amitriptyline, imipramine — block sodium and potassium channels.
- SSRIs: Citalopram and escitalopram carry the most notable QT risk within this class; the FDA issued a dose limitation warning for citalopram (maximum 40 mg/day in adults; 20 mg/day in elderly or hepatically impaired patients).
Antiemetics
- Ondansetron (Zofran): Commonly used for nausea; carries dose-dependent QT prolongation. IV formulations and high doses are the greatest concern.
- Domperidone: Available in many countries; significant QT risk led to restriction of its use in cardiac patients.
- Metoclopramide: Modest QT effect.
Other Notable Drugs
- Methadone: A significant QT-prolonging drug; risk scales with dose. ECG monitoring before and during therapy is recommended.
- Tamoxifen: Breast cancer treatment with modest QT prolongation.
- Arsenic trioxide: Leukemia treatment; requires intensive cardiac monitoring.
- Some antihistamines: Terfenadine and astemizole (both withdrawn from the US market due to TdP).
Risk Factors for Drug-Induced QT Prolongation
The combination of a QT-prolonging drug and individual risk factors substantially raises TdP risk:
- Female sex: Women have longer baseline QTc values and are approximately 2–3 times more likely than men to develop TdP from QT-prolonging drugs.
- Advanced age: Slowed cardiac conduction and reduced hERG channel reserve.
- Electrolyte abnormalities: Hypokalemia (low potassium) and hypomagnesemia profoundly increase QT risk — these are the most immediately correctable risk factors. Diuretics, vomiting, diarrhea, and poor nutrition can all deplete these electrolytes.
- Congenital long QT syndrome (LQTS): Inherited mutations in cardiac ion channels confer a baseline predisposition; even mild QT-prolonging drugs can trigger TdP.
- Bradycardia (slow heart rate): QT is already longer at slower rates; bradycardia exacerbates drug-induced prolongation.
- Structural heart disease: Heart failure, hypertrophic cardiomyopathy, myocardial ischemia.
- Hepatic or renal impairment: Reduced drug clearanceClearance
The volume of plasma from which a drug is completely removed per unit time, reflecting the body's efficiency at eliminating the drug. Clearance is primarily determined by liver metabolism and kidney e
leads to higher drug concentrations and greater channel blockade.
Drug Interactions and QT Risk
One of the most dangerous scenarios is the combination of two or more QT-prolonging drugs. The QT effects are often additive. Well-documented high-risk combinations include:
- Antipsychotic + macrolide antibiotic
- Methadone + fluoroquinolone
- Antiarrhythmic + antifungal (via CYP enzyme inhibitionEnzyme Inhibition
The process by which a drug decreases the activity of metabolizing enzymes, leading to slower breakdown and increased blood levels of co-administered drugs. Unlike induction, inhibition can occur rapi
increasing antiarrhythmic levels)
CYP3A4 enzyme inhibitors (fluconazole, ketoconazole, clarithromycin, grapefruit) can dramatically increase plasma concentrations of co-administered QT-prolonging drugs, compounding the cardiac risk even without a direct additive effect.
Before prescribing or dispensing a QT-prolonging drug, clinicians are encouraged to review a patient's complete medication list for potential interactions.
Symptoms to Watch For
Most patients with mildly prolonged QT intervals are asymptomatic. When QT prolongation becomes severe or triggers TdP, the following symptoms may occur:
- Palpitations: Sensations of rapid, pounding, or irregular heartbeat
- Lightheadedness or dizziness: Often preceding syncope
- Syncope (fainting): Sudden loss of consciousness, often brief; may be mistaken for seizure
- Chest fluttering or thumping
- Cardiac arrest: TdP that degenerates to ventricular fibrillation
These symptoms require emergency evaluation, especially in someone taking a known QT-prolonging drug. Call 911 immediately.
Monitoring and Risk Reduction
Before starting a QT-prolonging drug: - Obtain baseline ECG — document the QTc value. - Check and correct electrolytes (potassium, magnesium, calcium). - Review complete medication list for QT-prolonging drugs and CYP3A4 inhibitors. - Assess personal and family history of arrhythmia or sudden cardiac death.
During therapy: - Repeat ECG after reaching steady-state (typically 3–5 half-lives). - Threshold for concern: QTc >500 ms or an increase of >60 ms from baseline warrants dose reduction, drug discontinuation, or cardiology consultation. - Monitor electrolytes periodically, especially with concurrent diuretic use.
Risk reduction strategies: - Use the lowest effective dose of a QT-prolonging drug. - Correct hypokalemia and hypomagnesemia before and during therapy. - Avoid concurrent QT-prolonging drugs whenever possible. - Educate patients on symptoms requiring emergency evaluation.
CredibleMeds and Risk Categories
CredibleMeds (crediblemeds.org), operated by the Arizona CERT, maintains a continuously updated database of drugs classified by their QT/TdP risk:
- Known Risk: Drugs with convincing evidence of causing TdP.
- Conditional Risk: QT/TdP risk associated with risk factors (overdose, hypokalemia, interactions).
- Possible Risk: Evidence for QT prolongation exists; TdP link less established.
- Special Risk: Mostly safe, but risk in congenital long QT syndrome.
This database is an essential reference for clinicians managing patients on multiple medications and for patients who want to verify whether their drugs carry cardiac risk.
This guide is for educational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making changes to your medication regimen.